At a $687M market cap with a Price/Sales of 2 and Price/Book of 1.5, the market is pricing CSTL like a low-quality, uncertain asset despite a strong 4.2 Altman Z-Score that signals low bankruptcy risk. The absence of a Forward P/E and PEG ratio, combined with projected EPS of -$0.83 next year and negative operating margin of -5.10%, tells you the growth algorithm is broken in the near term. Yet the balance sheet strength (Current Ratio 5.3) and positive 12.80% ROE suggest this is not a distressed asset, but rather a mispriced transition story. This is not a growth compounder today, but it is also not financially impaired—meaning the market is discounting earnings instability more than solvency risk. The stock sits in valuation limbo: optically cheap on assets and sales, but fundamentally pressured on profitability trajectory.